Amino Acid Uptake and Metabolism by Larvae of the Marine Worm \u3ci\u3eUrechis caupo\u3c/i\u3e (Echiura), a New Species in Axenic Culture

Axenic (bacteria-free) larval cultures of the marine echiuran worm, Urechis caupo, were reliably obtained by aseptically removing gametes directly from the gamete storage organs. Trochophore larvae only removed neutral amino acids from seawater as measured by high-performance liquid chromatography (HPLC). There was no detectable uptake, as measured by HPLC, of acidic or basic amino acids. Kinetic analysis showed that the transport system for alanine in 4-day-old larvae had a Kt of 4-6 μM and a Jmax of 9-10 pmol larva-1 h-1. Following a 50-min exposure, the majority of the radio-activity (95%) from 14C-alanine was found in the trichlo-roacetic acid-soluble fraction. Very little label appeared as acid-insoluble material, and there was no detectable lipid biosynthesis from 14C-alanine. Approximately 12% of the total alanine transported was released in the form of 14CO2. Thin-layer chromatography of intracellular free amino acid pools demonstrated that aspartic acid and glutamic acid were radiolabeled from the alanine precursor. A comparison of the energy acquired from the transport of alanine, with the metabolic rate of 4-day-old larvae, revealed that 51% of the metabolic demand could be provided by the transport and complete catabolism of this single amino acid at a concentration of 595 nM in seawater. Originally published in Biological Bulletin and used with permission

Ontogenic Changes in the Rates of Amino Acid Transport from Seawater by Marine Invertebrate Larvae (\u3cem\u3eEchinodermata, Echiura, Mollusca\u3c/em\u3e)

Transport rates of amino acids were determined for larvae of different ages of the echiuran worm Urechis caupo, the gastropod Haliotis rufescens, the bivalve Crassostrea gigas, and the sea urchin Strongylocentrotus purpuratus. All larval forms showed an increase in the transport rate of amino acids during development. Trochophores of U. caupo increased their rate of net flux for each of 5 amino acids (100 nM each) by a factor of 1.6 and 2.2 during 1-3 days and 4-8 days, respectively, for two independent cultures. In H. rufescens, the maximum transport capacity (Jmax) for alanine increased 3-fold during the 24 h required for the trochophore to develop into a veliger. In C. gigas veligers, there was a 9-fold increase in the maximum transport capacity for alanine during larval development from an 80 μm to a 300 μm larva. In sea urchins, the prism-stage larvae (2-day-old) had an alanine transport system with a Kt of 1.9 μM and a Jmax of 8.1 pmol larvae -1h-1. The kinetics of alanine transport in the pluteus-stage (4-day-old) were best described by two systems (System I: Kt = 1.0 μM with a Jmax of 5.6 pmol larva -1h-1; System II: Kt = 132.0 μM with a Jmax of 8.4 pmol larva -1h-1). In larvae of C. gigas, the relationships between the rate of alanine transport and body size was described by the equation, log Jmax (pg larva-1h-1) = 1.6894(X) + (-0.5937), where X is the shell length in μm. It is illustrated that the allometric increased in respiration rates, during the growth of bivalve larvae, is matched by an ontogenic increase in amino acid transport capacity

Internal Friction of Amorphous Silicon in a Magnetic Field

The internal friction of e-beam amorphous silicon was measured in a magnetic field between 0 and 6 T, from 1.5-20 K, and was found to be independent of the field to better than 8%. It is concluded that the low energy excitations observed in this experiment are predominantly atomic in nature.Comment: 4 pages, 4 figures, REVTe

Detailed comparison of the pp -> \pi^+pn and pp -> \pi^+d reactions at 951 MeV

The positively charged pions produced in proton-proton collisions at a beam momentum of 1640 MeV/c were measured in the forward direction with a high resolution magnetic spectrograph. The missing mass distribution shows the bound state (deuteron) clearly separated from the $pn$ continuum. Despite the very good resolution, there is no evidence for any significant production of the $pn$ system in the spin-singlet state. However, the $\sigma(pp\to \pi^+pn)/\sigma(pp\to \pi^+d)$ cross section ratio is about twice as large as that predicted from $S$-wave final-state-interaction theory and it is suggested that this is due to $D$-state effects in the $pn$ system.Comment: 8 pages, 3 figure

Measurement of p + d -> 3He + eta in S(11) Resonance

We have measured the reaction p + d -> 3He + eta at a proton beam energy of 980 MeV, which is 88.5 MeV above threshold using the new ``germanium wall'' detector system. A missing--mass resolution of the detector system of 2.6% was achieved. The angular distribution of the meson is forward peaked. We found a total cross section of (573 +- 83(stat.) +- 69(syst.))nb. The excitation function for the present reaction is described by a Breit Wigner form with parameters from photoproduction.Comment: 8 pages, 2 figures, corrected typos in heade

A randomized trial of bevacizumab for newly diagnosed glioblastoma.

BACKGROUND: Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known. METHODS: In this randomized, double-blind, placebo-controlled trial, we treated adults who had centrally confirmed glioblastoma with radiotherapy (60 Gy) and daily temozolomide. Treatment with bevacizumab or placebo began during week 4 of radiotherapy and was continued for up to 12 cycles of maintenance chemotherapy. At disease progression, the assigned treatment was revealed, and bevacizumab therapy could be initiated or continued. The trial was designed to detect a 25% reduction in the risk of death and a 30% reduction in the risk of progression or death, the two coprimary end points, with the addition of bevacizumab. RESULTS: A total of 978 patients were registered, and 637 underwent randomization. There was no significant difference in the duration of overall survival between the bevacizumab group and the placebo group (median, 15.7 and 16.1 months, respectively; hazard ratio for death in the bevacizumab group, 1.13). Progression-free survival was longer in the bevacizumab group (10.7 months vs. 7.3 months; hazard ratio for progression or death, 0.79). There were modest increases in rates of hypertension, thromboembolic events, intestinal perforation, and neutropenia in the bevacizumab group. Over time, an increased symptom burden, a worse quality of life, and a decline in neurocognitive function were more frequent in the bevacizumab group. CONCLUSIONS: First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. Progression-free survival was prolonged but did not reach the prespecified improvement target. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00884741.)

Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine

DepoCyte is a slow-release formulation of cytarabine designed for intrathecal administration. The goal of this multi-centre cohort study was to determine the safety and efficacy of DepoCyte for the intrathecal treatment of neoplastic meningitis due to breast cancer. DepoCyte 50 mg was injected once every 2 weeks for one month of induction therapy; responding patients were treated with an additional 3 months of consolidation therapy. All patients had metastatic breast cancer and a positive CSF cytology or neurologic findings characteristic of neoplastic meningitis. The median number of DepoCyte doses was 3, and 85% of patients completed the planned 1 month induction. Median follow up is currently 19 months. The primary endpoint was response, defined as conversion of the CSF cytology from positive to negative at all sites known to be positive, and the absence of neurologic progression at the time the cytologic conversion was documented. The response rate among the 43 evaluable patients was 28% (CI 95%: 14–41%); the intent-to-treat response rate was 21% (CI 95%: 12–34%). Median time to neurologic progression was 49 days (range 1–515(+)); median survival was 88 days (range 1–515(+)), and 1 year survival is projected to be 19%. The major adverse events were headache and arachnoiditis. When drug-related, these were largely of low grade, transient and reversible. Headache occurred on 11% of cycles; 90% were grade 1 or 2. Arachnoiditis occurred on 19% of cycles; 88% were grade 1 or 2. DepoCyte demonstrated activity in neoplastic meningitis due to breast cancer that is comparable to results reported with conventional intrathecal agents. However, this activity was achieved with one fourth as many intrathecal injections as typically required in conventional therapy. The every 2 week dose schedule is a major advantage for both patients and physicians. © 2001 Cancer Research Campaign http://www.bjcancer.co

A precision determination of the mass of the η\eta meson

Several processes of meson production in proton-deuteron collisions have been measured simultaneously using a calibrated magnetic spectrograph. Among these processes, the $\eta$ meson is seen clearly as a sharp missing--mass peak on a slowly varying background in the $p+d\to ^3\textrm{He} +X$ reaction. Knowing the kinematics of the other reactions with well determined masses, it is possible to deduce a precise mass for the $\eta$ meson. The final result, $m(\eta)=547.311\pm 0.028 \textrm{(stat)} \pm 0.032 \textrm{(syst) MeV/c}^2$, is significantly lower than that found by the recent NA48 measurement, though it is consistent with values obtained in earlier counter experiments.Comment: 10 pages, 6 figures, Fig. 3 change